Female Reproductive System Neoplasm Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Female Reproductive System Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled475 locationsNCT05564377
Recruiting
Phase 1

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406
Recruiting
Phase 2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Anal CarcinomaCervical CarcinomaVaginal Carcinoma+3 more
Ohio State University Comprehensive Cancer Center25 enrolled1 locationNCT07407647
Recruiting
Not Applicable

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

Ovarian CarcinomaOvarian NeoplasmsFemale Reproductive System Adnexal Neoplasm+3 more
Mayo Clinic40 enrolled1 locationNCT07280312
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Not Applicable

Cancer Genetic Testing in Ethnic Populations

Breast CarcinomaHead and Neck CarcinomaMalignant Brain Neoplasm+8 more
Mayo Clinic1,800 enrolled2 locationsNCT04475640
Recruiting
Phase 3

REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss

Malignant Female Reproductive System NeoplasmAnxietySleep Disturbance+2 more
Wake Forest University Health Sciences160 enrolled2 locationsNCT05625360